AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Jun 23, 2025
30849_dirs_2025-06-23_e75d1fcc-27ad-441d-a564-b5406529a954.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-06-18
Reporting Person: Arbuckle Stuart A (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-18 | Common Stock | M | 4000 | — | Acquired | 7000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-18 | Restricted Stock Units | $ | M | 4000 | Disposed | Common Stock (4000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Board/Management Information
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3